2 Growth Stocks That Could Take Off in February

Novavax has been both a promising and frustrating stock to own recently. It's promising in the sense that its COVID-19 vaccine candidate could give the company a slice of what's proving to be a very large pie. The frustrating part about Novavax is that it has continually pushed back its schedule for applying to the U.S. Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA).